JOP20240195A1 - أشكال نقية من أتيكابرانت البلوري - Google Patents
أشكال نقية من أتيكابرانت البلوريInfo
- Publication number
- JOP20240195A1 JOP20240195A1 JOJO/P/2024/0195A JOP20240195A JOP20240195A1 JO P20240195 A1 JOP20240195 A1 JO P20240195A1 JO P20240195 A JOP20240195 A JO P20240195A JO P20240195 A1 JOP20240195 A1 JO P20240195A1
- Authority
- JO
- Jordan
- Prior art keywords
- aticabrant
- crystalline
- pure forms
- aticaprant
- solvates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240195A1 true JOP20240195A1 (ar) | 2024-09-05 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0195A JOP20240195A1 (ar) | 2022-03-07 | 2024-09-05 | أشكال نقية من أتيكابرانت البلوري |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (enExample) |
| EP (1) | EP4489748A1 (enExample) |
| JP (1) | JP2025508071A (enExample) |
| KR (1) | KR20240158951A (enExample) |
| CN (1) | CN119156210A (enExample) |
| AU (1) | AU2023231493A1 (enExample) |
| CA (1) | CA3254503A1 (enExample) |
| CL (1) | CL2024002643A1 (enExample) |
| CO (1) | CO2024012457A2 (enExample) |
| IL (1) | IL315411A (enExample) |
| JO (1) | JOP20240195A1 (enExample) |
| MX (1) | MX2024010978A (enExample) |
| PE (1) | PE20242109A1 (enExample) |
| TW (1) | TW202345795A (enExample) |
| WO (1) | WO2023170547A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709522B2 (en) * | 2008-01-22 | 2010-05-04 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| WO2022234457A1 (en) * | 2021-05-04 | 2022-11-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
-
2023
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20242109A1 (es) | 2024-10-28 |
| AU2023231493A1 (en) | 2024-10-24 |
| WO2023170547A1 (en) | 2023-09-14 |
| EP4489748A1 (en) | 2025-01-15 |
| CO2024012457A2 (es) | 2024-09-30 |
| CL2024002643A1 (es) | 2025-01-24 |
| CA3254503A1 (en) | 2023-09-14 |
| TW202345795A (zh) | 2023-12-01 |
| MX2024010978A (es) | 2024-12-06 |
| US20230348377A1 (en) | 2023-11-02 |
| US20250326714A1 (en) | 2025-10-23 |
| CN119156210A (zh) | 2024-12-17 |
| KR20240158951A (ko) | 2024-11-05 |
| IL315411A (en) | 2024-11-01 |
| JP2025508071A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010978A (es) | Formas puras de aticaprant cristalino | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| MX2025015367A (es) | Inhibidores del oncogen del sarcoma de rata de kirsten (kras) | |
| PH12023500015A1 (en) | Irak degraders and uses thereof | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| PH12023500023A1 (en) | Cdk2 degraders and uses thereof | |
| MX2025015277A (es) | Inhibidores de masp-2 y metodos de uso | |
| MX2023014154A (es) | Anticuerpos anti-ccr8. | |
| CO2024004970A2 (es) | Agentes degradantes de tyk2 y sus usos | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
| MX2025006853A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos | |
| MX2020009147A (es) | Moduladores de la expresion de irf4. | |
| MX2025006791A (es) | Agente de iarn con nucleótidos modificados | |
| MX2024014079A (es) | Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| MX2022007190A (es) | Analogos de cistina diamida para la cistinuria. | |
| CL2025003307A1 (es) | Inhibidores de mrgprx2 y sus métodos de uso. | |
| BR112021019448A2 (pt) | Métodos para o tratamento de beta-talassemia | |
| MX2023014984A (es) | Anticuerpos anti-csp. | |
| MX2025012761A (es) | Moleculas y metodos de uso de estas | |
| CL2024002103A1 (es) | Métodos para tratar amiloidosis al |